Active Ingredient(s): Ibalizumab-uiyk
FDA Approved: * March 6, 2018
Category: HIV / AIDS

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Trogarzo Overview

Ibalizumab (trade name Trogarzo) is a non-immunosuppressive monoclonal antibody that binds CD4, the primary receptor for HIV, and inhibits the viral entry process.[2] It is being investigated as an HIV entry inhibitor[3] with the ability to block both CCR5- and CXCR4-tropic viruses,[4] and is undergoing a Phase II clinical trial with an estimated study completion date in December 2010.[5] Specific research is also conducted at th...

Read more Trogarzo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Trogarzo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 150mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Trogarzo: (1 result)

Sorted by National Drug Code
  • 62064-122 Trogarzo 150 mg/ml Intravenous Injection, Solution by Theratechnologies Inc.

Other drugs which contain Ibalizumab-uiyk or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 19 October 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 501 S. Cherry St, Suite 1100, Denver, CO, 80246, USA